The Role of Galactosemia Mismanagement in Catastrophic Infant Harm

Once recognized, classic galactosemia is one of the few neonatal disorders that has a straightforward treatment: the elimination of galactose from the infant’s diet.  Therefore, if an infant develops liver failure, sepsis, permanent neurological injury, or dies after birth, questions about the galactosemia diagnosis rise. Given the presence of the metabolic disorder, why did this particular outcome occur? Furthermore, did the infant continue receiving the very substance causing the injury because the diagnosis evolved more slowly than the physiology?

Identifying the point when galactosemia mismanagement occurred—be it inconsistencies in treatment or something else—ultimately determines whether the case represents an unavoidable consequence of a rare genetic disease or a preventable delay in care.

The Central Dispute: Did Differential Diagnosis Change Fast Enough?

Galactosemia begins with symptoms that may point to other conditions. Poor feeding, vomiting, lethargy, hypoglycemia, homeostatic instability, or respiratory distress reasonably prompt investigation for infection or other neonatal disorders. However, it may take some time before the clinical team lands on galactosemia.

This is why the infant’s continued deterioration is scrutinized. How long did it take for the range of reasonable explanations to narrow to the point that galactosemia was named?

As additional laboratory abnormalities develop, liver dysfunction worsens, feeding intolerance persists, or metabolic acidosis progresses, the medical record may begin documenting a pattern that no longer fits the original working diagnosis. At the point, medical experts may examine whether the differential diagnosis should have expanded to include metabolic errors or if additional feedings should have continued.

The significance of the delay therefore lies not in the passage of time itself, but in whether each additional feeding occurred after the available evidence suggested clinicians were confronting a fundamentally different disease process.

Continued Feeding May Become the Most Significant Medical Decision

Galactosemia only progresses as more galactose is consumed. Therefore, a unique question is often considered: Did ongoing treatment contribute to the infant’s worsening physiology?

Every subsequent feeding that contains lactose will also provide galactose into a system that cannot adequately metabolize it. As the metabolites accumulate, the liver becomes taxed and dysfunctional. Metabolic instability may increase, leading to accelerated deterioration rather than mitigation.

An individual feeding may not be enough for clinicians to detect galactosemia. When the feeding record is viewed as a collection, however, it may demonstrate that repeated exposure  to milk had already begun pointing toward a metabolic disorder rather than an infection or disease.

Litigators must examine not only what clinicians knew but what actions continued after the amount of available evidence increased.

Newborn Screening May Not Resolve the Timing Question

Among the primary tools used to identify galactosemia, newborn screenings are one of the most common. However, it rarely answers the questions that appear in the courtroom: did the infant’s condition continue to deteriorate while the care team awaited the result?

Newborn screenings are designed to identify disorders across large populations rather than guide a minute-by-minute treatment for a critically ill infant. Thus, there are periods where the infant remains symptomatic and with an uncertain diagnosis while the test is pending. So it becomes relevant to ask what the clinicians did during that interval? Did they continue to feed the newborn? If so, did the medical record ever indicate that continued feedings were more risky than beneficial?

Experts pay a substantial amount of attention to the worsening clinical picture rather than a pending diagnosis. A defense expert may explain that medicine cannot safely abandon established neonatal care protocols every time the possibility of a disorder or disease arises. The plaintiff’s expert, however, may state that the differential diagnosis had already narrowed because the infant’s physiology did not fit a more common explanation.

From that perspective, waiting is not causation, it is prolonged exposure to the very substance driving the infant’s deterioration.

When Did the Case Stop Looking Like Sepsis?

Frequently, galactosemia presents as neonatal sepsis. The similarity makes the initial investigation and diagnosis reasonable from a medical point of view. In court, it becomes relevant to consider when the infant’s deterioration stopped supporting the sepsis diagnosis and when the medical team took notice.

Persistent liver dysfunction despite antibiotic therapy, worsening coagulopathy, feeding intolerance, hypoglycemia, rising bilirubin levels, abnormal metabolic studies, or failure to improve despite treatment may gradually reveal that infection alone no longer explains the infant’s condition.

To understand when the diagnosis should have changed, experts often reconstruct the chronology of the case.

Could Earlier Intervention Have Interrupted the Injury?

No every delayed diagnosis produces the same legal significance. Some infants may develop an irreversible injury before uncertainty about their condition can be resolved. In the case of galactosemia mismanagement, an infant may continue receiving galactose despite findings that may have justified earlier dietary modification.

Accordingly, experts will evaluate whether the disputed delay occurred while the infant remained physically capable of benefiting from intervention. The litigation aims to determine whether continued exposure during that period probably contributed to the catastrophic outcome.

Conclusion

Galactosemia mismanagement cases rarely turn on the diagnosis alone. Instead, they require determining whether the infant’s clinical deterioration progressively undermined the original working diagnosis and whether continued galactose exposure occurred after the medical record suggested that a metabolic disorder should have been actively considered. Resolving that dispute often requires integrating feeding records, laboratory studies, newborn screening, clinical observations, and expert testimony into a single chronology explaining not only how the injury progressed, but whether earlier recognition and dietary intervention would probably have prevented catastrophic harm.

Raynes & Lawn evaluates birth injury and neonatal malpractice cases involving delayed diagnosis, metabolic disorders, neonatal liver injury, sepsis, hypoglycemia, and other catastrophic conditions affecting newborns. These matters frequently depend upon determining whether evolving clinical evidence should have prompted a different diagnostic approach or earlier intervention before preventable injury continued to progress.